中国药业
中國藥業
중국약업
CHINA PHARMACEUTICALS
2015年
16期
64-64,65
,共2页
罗雪香%徐玉红%何剑琴%何英%冯风明%郭华
囉雪香%徐玉紅%何劍琴%何英%馮風明%郭華
라설향%서옥홍%하검금%하영%풍풍명%곽화
幽门螺杆菌%胃溃疡%莫西沙星%阿莫西林
幽門螺桿菌%胃潰瘍%莫西沙星%阿莫西林
유문라간균%위궤양%막서사성%아막서림
Helicobacter pylori%gastric ulcer%moxifloxacin%amoxicillin
目的:比较莫西沙星与阿莫西林治疗幽门螺杆菌相关性胃溃疡的临床疗效。方法选取医院2012年收治的幽门螺杆菌相关性胃溃疡患者60例,采用随机数字表法分为观察组及对照组,各30例。两组患者均进行常规治疗,观察组和对照组分别加服莫西沙星与阿莫西林。结果观察组的幽门螺杆菌根除率为70.00%,明显高于对照组的50.00%( P<0.05)。观察组的病灶愈合率为96.67%,与对照组的90.00%相比较,差异无统计学意义( P>0.05)。结论莫西沙星治疗幽门螺杆菌相关性胃溃疡的疗效较阿莫西林更佳,且在治疗期间未出现不良反应,安全性好,值得临床推广。
目的:比較莫西沙星與阿莫西林治療幽門螺桿菌相關性胃潰瘍的臨床療效。方法選取醫院2012年收治的幽門螺桿菌相關性胃潰瘍患者60例,採用隨機數字錶法分為觀察組及對照組,各30例。兩組患者均進行常規治療,觀察組和對照組分彆加服莫西沙星與阿莫西林。結果觀察組的幽門螺桿菌根除率為70.00%,明顯高于對照組的50.00%( P<0.05)。觀察組的病竈愈閤率為96.67%,與對照組的90.00%相比較,差異無統計學意義( P>0.05)。結論莫西沙星治療幽門螺桿菌相關性胃潰瘍的療效較阿莫西林更佳,且在治療期間未齣現不良反應,安全性好,值得臨床推廣。
목적:비교막서사성여아막서림치료유문라간균상관성위궤양적림상료효。방법선취의원2012년수치적유문라간균상관성위궤양환자60례,채용수궤수자표법분위관찰조급대조조,각30례。량조환자균진행상규치료,관찰조화대조조분별가복막서사성여아막서림。결과관찰조적유문라간균근제솔위70.00%,명현고우대조조적50.00%( P<0.05)。관찰조적병조유합솔위96.67%,여대조조적90.00%상비교,차이무통계학의의( P>0.05)。결론막서사성치료유문라간균상관성위궤양적료효교아막서림경가,차재치료기간미출현불량반응,안전성호,치득림상추엄。
Objective To compare tbe clinical effects between moxifloxacin and amoxicillin in treating Helicobacter pylori(HP)associated gastric ulcer. Methods Totally 60 patients witb HP associated gastric ulcer admitted to tbe bospital in 2012 were randomly divided in-to tbe observation group and tbe contorl group,30 cases in eacb group Tbe two groups were peformed tbe routine tberapy. Tbe observa-tion group and tbe contorl group were given moxifloxaclin and amoxicillin respectiveey. Results Tbe HP eradication rate was 70. 00%of tbe observation group,wbicb was significantly bigber tban 50. 00% of tbe contorl group( P < 0. 05). Tbe lesion bealing rate was 96. 67% in tbe observation group and 90. 00% in tbe contorl group,tbe difference between tbe two groups bad no statistical signifi-cance( P > 0. 05). Conclusion Tbe clinical effect of moxifloxacin in treating HP associated gastric ulcer is more significant tban amox-icillin,and witbout adverse reactions during treatment. It is safe and wortby of clinical promotion.